Pertussis

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2025-06-05
Clinical Trial Update: Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) [Phase 3]
Phase 3 trial evaluating a pentavalent DTP-HB-Hib vaccine for immunogenicity and safety has been withdrawn.
CLINICAL_TRIALS withdrawal · 2015-10-09
Clinical Trial Update: A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN) [Phase 3]
A Phase 3 study evaluating immunogenicity and safety of a whole-cell pertussis–containing vaccine given with Rotarix or RotaTeq has been wit…
EMA withdrawal · 2008-09-10
EMA Withdrawn: Quintanrix (Diphtheria toxoid;tetanus toxoid;inactivated Bordetella pertussis;hepatitis B surface antigen (rDNA);Haemophilus influenzae type b polysaccharide) — GlaxoSmithKline Biologicals S.A.
Quintanrix has been withdrawn from the market by GlaxoSmithKline Biologicals S.A., with the status indicating withdrawal for its diphtheria,…